Clinical Trial Detail

NCT ID NCT03329846
Title An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

BMS-986205 + Nivolumab

Nivolumab

Age Groups: adult child senior

No variant requirements are available.